Hepatitis B and C infection in international travelers

Journal of Travel Medicine

Volumn 20, Issue 3, 2013, Pages 194-202

  Johnson, Douglas F ^a   Leder, Karin ^b,c   Torresi, Joseph ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRIX; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DRUG ABUSE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; INFECTION PREVENTION; INFECTION RISK; MEDICAL DEVICE; PREVALENCE; PREVENTIVE MEDICINE; REVIEW; SALIVA; SPERM; TOURISM; TRAVEL; VACCINATION; VERTICAL TRANSMISSION; VIRAL CONTAMINATION; VIRUS TRANSMISSION;

DISEASE TRANSMISSION, INFECTIOUS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; INCIDENCE; INTERNATIONALITY; PATIENT COMPLIANCE; PREVALENCE; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; TRAVEL; WORLD HEALTH;

EID: 84876286108     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12026     Document Type: Review

References (88)

1. UNWTO. UNWTO tourism highlights, 2012 edition. 2012. Available at: http://dtxtq4w60xqpw.cloudfront.net/sites/all/files/docpdf/ unwtohighlights12enlr-1.pdf. (Accessed 2013 Mar 20)
2. Curry M, Chopra S,. Acute viral hepatitis. In:, Mandell G, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th Ed. Philadelphia: Churchill Livingstone Elsevier, 2010: 1582-1584.
3. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
4. Koziel MJ, Thio CL,. Hepatitis B virus and hepatitis delta virus. In:, Mandell G, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th Ed. Philadelphia: Churchill Livingstone Elsevier, 2010: 2059-2086.
5. Nguyen VT, Razali K, Amin J, et al. Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. J Gastroenterol Hepatol 2008; 23: 922-929.
6. Rots NY, Wijmenga-Monsuur AJ, Luytjes W, et al. Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations. Vaccine 2010; 28: 893-900.
7. WHO. Progress towards meeting the 2012 hepatitis B control milestone: WHO Western Pacific region, 2011. Wkly Epidemiol Rec 2011; 19:177-188. Available at: http://www.who.int/wer/2011/wer8619.pdf. (Accessed 2013 Mar 20)
8. Gidding HF, Warlow M, MacIntyre CR, et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 2007; 25: 8637-8641.
9. WHO. Global immunization 1989-2010, 3rd dose of hepatitis B coverage in infants. 2010. Available at: http://www.who.int/immunization-monitoring/ diseases/HepB-coverage.jpg. (Accessed 2013 Mar 20)
10. Su FH, Chen JD, Cheng SH, et al. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat 2008; 15: 14-19.
11. Banatvala J, Van Damme P, Emiroglu N,. Hepatitis B immunisation in Britain: time to change? BMJ 2006; 332: 804-805.
12. Leder K, Chen LH, Wilson ME,. Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine 2012; 30: 2600-2604.
13. National Hepatitis B Strategy 2010-2013. 2010. Available at: http://www.ashm.org.au/images/first-national-hepatitis-b
14. NHMRC. The Australian immunisation handbook. 9th Ed. Canberra: Australian Government Department of Health and Ageing, National Health and Medical Research Council, 2008. Available at: http://health.gov.au/internet/immunise/ publishing.nsf/Content/Handbook-home. (Accessed 2013 Mar 20)
15. Edmunds WJ, Medley GF, Nokes DJ, et al. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993; 253: 197-201.
16. Loscher T, Keystone JS, Steffen R,. Vaccination of travelers against hepatitis A and B. J Travel Med 1999; 6: 107-114.
17. Steffen R, Banos A, de Bernardis C,. Vaccination priorities. Int J Antimicrob Agents 2003; 21: 175-180.
18. Torresi J, Johnson D,. Hepatitis A and E infection in international travellers. Curr Infect Dis Rep 2011; 13: 248-255.
19. Struve J, Norrbohm O, Stenbeck J, et al. Risk factors for hepatitis A, B and C virus infection among Swedish expatriates. J Infect 1995; 31: 205-209.
20. Streeton CL, Zwar N,. Risk of exposure to hepatitis B and other blood-borne viruses among Australians who travel abroad. J Travel Med 2006; 13: 345-350.
21. Hahne S, Ramsay M, Balogun K, et al. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 2004; 29: 211-220.
22. Sonder GJ, van Rijckevorsel GG, van den Hoek A,. Risk of hepatitis B for travelers: is vaccination for all travelers really necessary? J Travel Med 2009; 16: 18-22.
23. Steffen R, Connor BA,. Vaccines in travel health: from risk assessment to priorities. J Travel Med 2005; 12: 26-35.
24. Nielsen US, Petersen E, Larsen CS,. Hepatitis B immunization coverage and risk behaviour among Danish travellers: are immunization strategies based on single journey itineraries rational? J Infect 2009; 59: 353-359.
25. Boggild AK, Castelli F, Gautret P, et al. Vaccine preventable diseases in returned international travelers: results from the Geosentinel surveillance network. Vaccine 2010; 28: 7389-7395.
26. Vivancos R, Abubakar I, Hunter PR,. Foreign travel, casual sex, and sexually transmitted infections: systematic review and meta-analysis. Int J Infect Dis 2010; 14: e842-e851.
27. Cabada MM, Mozo K, Pantenburg B, Gotuzzo E,. Excessive alcohol consumption increases risk taking behaviour in travellers to Cusco, Peru. Travel Med Infect Dis 2011; 9: 75-81.
28. Smalligan RD, Lange WR, Frame JD, et al. The risk of viral hepatitis A, B, C, and E among North American missionaries. Am J Trop Med Hyg 1995; 53: 233-236.
29. Ohara H, Ebisawa I, Naruto H,. Prophylaxis of acute viral hepatitis by immune serum globulin, hepatitis B vaccine, and health education: a sixteen year study of Japan overseas cooperation volunteers. Am J Trop Med Hyg 1997; 56: 76-79.
30. Khuroo MS,. Viral hepatitis in international travellers: risks and prevention. Int J Antimicrob Agents 2003; 21: 143-152.
31. Steffen R,. Risk of hepatitis A in travellers. Vaccine 1992; 10 (Suppl 1): S69-S72.
32. Nielsen US, Thomsen RW, Cowan S, et al. Predictors of travel-related hepatitis A and B among native adult Danes: a nationwide case-control study. J Infect 2012; 64: 399-408.
33. Johnson DF, Ratnam I, Matchett E, et al. The incidence of HBV and HCV infection in Australian travelers to Asia. J Travel Med 2013; 20: XX-XX.
34. Leggat PA, Zwar NA, Hudson BJ,. Hepatitis B risks and immunisation coverage amongst Australians travelling to southeast Asia and east Asia. Travel Med Infect Dis 2009; 7: 344-349.
35. Mulhall BP, Hu M, Thompson M, et al. Planned sexual behaviour of young Australian visitors to Thailand. Med J Aust 1993; 158: 530-535.
36. Zuckerman JN, Steffen R,. Risks of hepatitis B in travelers as compared to immunization status. J Travel Med 2000; 7: 170-174.
37. Evans RW,. Ethnocentrism is an unacceptable rationale for health care policy: a critique of transplant tourism position statements. Am J Transplant 2008; 8: 1089-1095.
38. Polcari AJ, Hugen CM, Farooq AV, et al. Transplant tourism-a dangerous journey? Clin Transplant 2011; 25: 633-637.
39. Alghamdi SA, Nabi ZG, Alkhafaji DM, et al. Transplant tourism outcome: a single center experience. Transplantation 2010; 90: 184-188.
40. CCDR. Canada communicable disease report statement on hepatitis vaccines for travellers. 2008. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr- rmtc/08pdf/acs-2.pdf. (Accessed 2013 Mar 20)
41. Kennedy SE, Shen Y, Charlesworth JA, et al. Outcome of overseas commercial kidney transplantation: an Australian perspective. Med J Aust 2005; 182: 224-227.
42. The Living Non-related Renal Transplant Study Group. Commercially motivated renal transplantation: results in 540 patients transplanted in India. Clin Transplant 1997; 11: 536-544.
43. Teshale E. Infectious diseases related to travel hepatitis B. 2011. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious- diseases-related-to-travel/hepatitis-b.htm. (Accessed 2013 Mar 20)
44. WHO. International travel and health. 2012. Available at: http://www.who.int/ith/en/. (Accessed 2013 Mar 20)
45. Zuckerman JN, Van Damme P, Van Herck K, Loscher T,. Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. Travel Med Infect Dis 2003; 1: 219-226.
46. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384.
47. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142: 333-341.
48. Lin HH, Wang LY, Hu CT, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003; 69: 471-474.
49. Yuen MF, Lim WL, Chan AO, et al. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2: 941-945.
50. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
51. Van Damme P, Van Herck K,. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5: 79-84.
52. European Medicines Agency. HBVAxpro. 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000373/human-med-000813.jsp&mid=WC0b01ac058001d124. (Accessed 2013 Mar 20)
53. GlaxoSmithKline. Vaccines fendrix. 2010. Available at: http://hcp.gsk.co.uk/products/fendrix.html. (Accessed 2013 Mar 20)
54. Murdoch DL, Goa K, Figgitt DP,. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs 2003; 63: 2625-2649.
55. Wolters B, Muller T, Ross RS, et al. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin 2009; 5: 248-253.
56. European Medicines Agency. Ambrix. 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000426/human-med-000645.jsp&mid=WC0b01ac058001d124. (Accessed 2013 Mar 20)
57. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International committee on virus taxonomy. Arch Virol 1998; 143: 2493-2503.
58. Torresi J, Bharadwaj M, Jackson DC, Gowans EJ,. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr Drug Targets 2004; 5: 41-56.
59. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
60. Rosen HR,. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429-2438.
61. WHO. Hepatitis C factsheet. 2011. Available at: http://www.who.int/ mediacentre/factsheets/fs164/en/. (Accessed 2013 Mar 20)
62. Strickland GT,. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006; 43: 915-922.
63. Holmberg S. Centers for Disease Control and Prevention travellers health hepatitis C. 2011. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2012/ chapter-3-infectious-diseases-related-to-travel/hepatitis-c.htm. (Accessed 2013 Mar 20)
64. WHO. Hepatitis C surveillance and control. 2003. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html. (Accessed 2013 Mar 20)
65. McHutchison JG,. Understanding hepatitis C. Am J Manag Care 2004; 10 (2 Suppl): S21-S29.
66. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230-238.
67. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
68. Hutin YJ, Hauri AM, Armstrong GL,. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003; 327: 1075.
69. WHO. Safe injection global network. Available at: http://www.who.int/ injection-safety/sign/en/. (Accessed 2013 Mar 20)
70. Thomas HC, Lemon SM, Zuckerman AJ,. Viral hepatitis. 3rd Ed. Malden: Blackwell Publishing, 2005.
71. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98-104.
72. Plotkin SA, Orenstein WA, Offit PA,. Vaccines. 5th Ed. Philadelphia: Saunders/Elsevier, 2008.
73. Hansen HL, Andersen PL, Brandt L, Brolos O,. Antibodies against hepatitis viruses in merchant seamen. Scand J Infect Dis 1995; 27: 191-194.
74. McCoy CB, Metsch LR, Chitwood DD, Miles C,. Drug use and barriers to use of health care services. Subst Use Misuse 2001; 36 (6-7): 789-806.
75. Des Jarlais DC, Torrico C, Settembrino J. Travel patterns among young urban nomad injecting drug users (IDUs) in the United States. In: The 130th Annual Meeting of the APHA; 2002; Philadelphia, PA.
76. Hahn JA, Page-Shafer K, Ford J, et al. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend 2008; 93 (1-2): 43-50.
77. Jaureguiberry S, Grandiere-Perez L, Ansart S, et al. Acute hepatitis C virus infection after a travel in India. J Travel Med 2005; 12: 55-56.
78. Bollepalli S, Wisinger D, Markov M, et al. Travel: a unique risk factor for acute hepatitis C virus. MedGenMed 2006; 8: 17.
79. Ghafur A, Raza M, Labbett W, et al. Travel-associated acquisition of hepatitis C virus infection in patients receiving haemodialysis. Nephrol Dial Transplant 2007; 22: 2640-2644.
80. Bhattacharya S, Price N, Boxall E, et al. Holiday haemodialysis and imported hepatitis C virus infection: a series of sixteen cases in two large haemodialysis units. J Clin Virol 2009; 45: 296-299.
81. Tu AW, Buxton JA, Whitlock M, et al. Prevalence and incidence of hepatitis C virus in hemodialysis patients in British Columbia: follow-up after a possible breach in hemodialysis machines. Can J Infect Dis Med Microbiol 2009; 20: e19-e23.
82. Castelli F,. Human mobility and disease: a global challenge. J Travel Med 2004; 11: 1-2.
83. CDC. CDC health information for international travel 2011-hepatitis B. 2011. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3- infectious-diseases-related-to-travel/hepatitis-b/canada.htm. (Accessed 2013 Mar 20)
84. CDC. CDC health information for international travel 2011-hepatitis C. 2011. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3- infectious-diseases-related-to-travel/hepatitis-c.htm. (Accessed 2013 Mar 20)
85. Van Damme P, Vorsters A,. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002; 67: 433-439.
86. Luo Z, Li L, Ruan B,. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012; 16: e82-e88.
87. Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21 (7-8): 685-691.
88. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). 1991. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00033405.htm. (Accessed 2013 Mar 20)